Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab

• Главные авторы: Angela J. Okragly (Автор), Aya Ryuzoji (Автор), Isabella Wulur (Автор), Montanea Daniels (Автор), Robert D. Van Horn (Автор), Chetan N. Patel (Автор), Robert J. Benschop (Автор)
• Формат: ‌
• Опубликовано: Adis, Springer Healthcare, 2023-06-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Introduction IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13. Methods We undertook studies to compare i...